B. Riley Securities analyst Madison Elsaadi maintained a Buy rating on Ovid Therapeutics today and set a price target of $5.00. The company’s shares closed today at $1.74.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Elsaadi is a 4-star analyst with an average return of 23.9% and a 68.42% success rate. Elsaadi covers the Healthcare sector, focusing on stocks such as Ovid Therapeutics, Arrowhead Pharmaceuticals, and Capricor Therapeutics.
Currently, the analyst consensus on Ovid Therapeutics is a Strong Buy with an average price target of $4.33, a 148.85% upside from current levels. In a report released today, Oppenheimer also initiated coverage with a Buy rating on the stock with a $7.00 price target.
The company has a one-year high of $2.01 and a one-year low of $0.24. Currently, Ovid Therapeutics has an average volume of 3.06M.
Read More on OVID:
Disclaimer & DisclosureReport an Issue
- Ovid Therapeutics initiated with an Outperform at Oppenheimer
- Ovid Therapeutics Secures $175.1M in Private Placement
- Morning Movers: Apple shares slip following Jefferies downgrade
- Ovid Therapeutics prices private placement up to $175M in gross proceeds
- Ovid Therapeutics announces results for Phase 1 study of OV329
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
